Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carrie Frame

Podiatrist, Foot & Ankle Surgery Charleston, WV Doctor of Podiatric Medicine

NPI 1992904270 CMS profile 226518

1 Kenton Dr Ste 100, Charleston, WV 25311

Open in the dashboard

General payments

$99,012

381 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Frame of Charleston, WV is reported in the CMS Open Payments database as having received $99,012 across 381 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,242 82
2024 General $17,388 78
2023 General $8,912 34
2022 General $16,302 47
2021 General $6,525 36
2020 General $11,651 42
2019 General $11,992 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Frame
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Carrie Frame were reported at $26,242. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Carrie Frame Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $11,992 $389 $118–$1,406 $163
2020 $11,651 $191 $62–$691 $114
2021 $6,525 $329 $104–$1,341 $132
2022 $16,302 $419 $125–$1,611 $149
2023 $8,912 $377 $128–$1,164 $160
2024 $17,388 $394 $134–$1,168 $164
2025 $26,242 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $94,540 261 payments
  2. Mid-Atlantic Surgical Systems, LLC $1,545 12 payments
  3. Arthrex, Inc. $807 16 payments
  4. Amgen Inc. $410 19 payments
  5. Smith+Nephew, Inc. $355 17 payments
  6. Paratek Pharmaceuticals, Inc. $264 13 payments
  7. Tactile Systems Technology Inc $185 5 payments
  8. Vaporox, Inc. $143 2 payments
  9. AbbVie, Inc. $101 6 payments
  10. Melinta Therapeutics, Inc. $100 7 payments
  11. Other $561 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,974 32 payments
  2. Consulting Fee $23,975 8 payments
  3. Travel and Lodging $15,058 54 payments
  4. Food and Beverage $8,255 283 payments
  5. Honoraria $6,750 4 payments
Products named General payments · program years 2019–2025
  1. Affinity $38,645 31 payments
  2. NOVACHOR $37,527 29 payments
  3. PURAPLY WOUND MATRIX $34,306 32 payments
  4. APLIGRAF Wound Care $32,101 21 payments
  5. Puraply $28,068 111 payments
  6. NuShield $22,192 15 payments
  7. CYGNUS DUAL $16,623 21 payments
  8. Puraply Antimicrobial $13,168 18 payments
  9. Apligraf Podiatry $10,434 19 payments
  10. Puraply/Affinity/NuTech $10,434 19 payments
  11. Other $20,353 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

401

Median for Podiatry: 160

Drug cost

$217,506

Median for Podiatry: $2,368

Branded share of claims

50.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuzyra Omadacycline Tosylate Brand 20 $155,187
Daptomycin Generic 38 $34,058
Ertapenem Ertapenem Sodium Brand 17 $12,857
Linezolid Generic 15 $8,310
Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam Brand 13 $4,077
Doxycycline Monohydrate Generic 19 $641
Doxycycline Hyclate Generic 38 $577
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 85 $568
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 31 $388
Gabapentin Generic 37 $341

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$2,717,748

Of which drugs: $2,618,716

Medicare patients

234

Average age 73

Services billed

7,701

155 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 40%
Ischemic heart disease 39%
Depression 36%
Chronic kidney disease 34%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Cygnus dual, per square centimeter Q4282 Office 30 2,862 $1,799,496
Puraply xt, per square centimeter Q4197 Office 23 2,551 $211,277
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 600 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $175
$175 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $60
$60 20 —
XERAVA
  • La Jolla Pharmaceutical Company $26
$26 — —
DALVANCE
  • AbbVie, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

381 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record